Company intelligence / Profile preview

ROXALL Medizin GmbH

Oststeinbek, Schleswig-Holstein, Germany

Ownership: Private
Employees: ~263
Development stage: Phase 3

Overview

The company has several immunotherapy products in development, with their Birch cluster immunotherapy currently in Phase 2 clinical trials for allergic conjunctivitis. Their dust mite allergen immunotherapy has been discontinued, while grass pollen allergy immunotherapy is pending approval.

Therapeutic areas: Immunology
Modalities: Biological productsImmunotherapiesSmall molecule
Industry: Biotech

Drug pipeline

16 assets

allergovac depot

Approved

15 more assets in the full pipeline.

Request access →

Partnerships

Inmunotek SLDr Beckmann Pharma GmbHBIAL-Portela & Cia SA

Beyond the preview

Go deeper on ROXALL Medizin GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ROXALL Medizin GmbH.

Explore the full profile